Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

  title={Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.},
  author={Jordan J Feld and I M for the New Paradigm of HCV Therapy Meeting Part Jacobson and Christophe H{\'e}zode and Tarik Asselah and Peter J Ruane and Norbert Gruener and Armand Abergel and Alessandra Mangia and Ching-lung Lai and Henry L. Y. Chan and Francesco Mazzotta and Christophe Moreno and Eric M Yoshida and Stephen D Shafran and William James Towner and Tram Anh T. Tran and John McNally and Anu O Osinusi and Evguenia S. Svarovskaia and Yanni Zhu and Diana M. Brainard and John McHutchison and Kosh Agarwal and Stefan Zeuzem},
  journal={The New England journal of medicine},
  volume={373 27},
BACKGROUND A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need. METHODS We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis. Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS


Publications citing this paper.
Showing 1-10 of 209 extracted citations


Publications referenced by this paper.
Showing 1-10 of 16 references

Hepatitis C virus The New England Journal of Medicine Downloaded from by JULES

  • AJ Muir, S. Naggie
  • LEVIN on November
  • 2015

Similar Papers

Loading similar papers…